- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02284191
Rapid Assessment of Potential Ischaemic Heart Disease With CTCA (RAPID-CTCA)
The Role of Early CT Coronary Angiography in the Evaluation, Intervention and Outcome of Patients Presenting to the Emergency Department With Suspected or Confirmed Acute Coronary Syndrome.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
DESIGN: Open parallel group randomised controlled trial of early computed tomography coronary angiography (CTCA) in patients presenting with suspected/confirmed acute coronary syndrome (ACS) to Emergency Departments (ED) and Medical Assessment Units.
SETTING: 37 EDs, radiology, cardiology and acute medical services in tertiary/district general National Health Service (NHS) hospitals.
TARGET POPULATION: Inclusion Criteria: Patient ≥18 years with symptoms mandating investigation for suspected or confirmed ACS with at least one of: ECG abnormalities e.g. ST segment depression >0.5 mm; History of ischaemic heart disease (where the clinician assessing patient confirms history based on patient history or available records); Troponin elevation above the 99th centile of the normal reference range or increase in high sensitivity troponin meeting European Society of Cardiology criteria for 'rule-in' or myocardial infarction (NB troponin assays will vary from site to site; local laboratory reference standards will be used). Exclusion Criteria: 1.Signs, symptoms, or investigations supporting high-risk ACS: ST elevation MI; ACS with signs or symptoms of acute heart failure or circulatory shock; Crescendo episodes of typical anginal pain; Marked or dynamic ECG changes e.g. ST depression of >3 mm; Clinical team have scheduled early invasive coronary angiography on day of trial eligibility assessment. 2. Patient inability to undergo CT: Severe renal failure (serum creatinine >250 µmol/L or estimated glomerular filtration rate <30 mL/min); Contrast allergy; Beta blocker intolerance (if no alternative heart rate limiting agent available/suitable) or allergy; Inability to breath hold; Atrial fibrillation (where mean heart rate is anticipated to be greater than 75 beats per minute after beta blockade). 3. Patient has had invasive coronary angiography or CTCA within last 2 years and the previous investigation revealed obstructive coronary artery disease, or patient had either investigation within the last 5 years and the result was normal. 4.Previous recruitment to the trial; 5.Known pregnancy or currently breast feeding; 6. Inability to consent; 7.Further investigation for ACS would not in the patient's interest, due to limited life expectancy, quality of life or functional status; 8.Prisoners
HEALTH TECHNOLOGIES BEING ASSESSED: Early use of ≥64-slice CTCA as part of routine assessment compared to standard care.
MEASUREMENT OF COSTS/OUTCOMES: Primary end-point will be one-year all-cause death or subsequent type 1 or type 4b MI at one year, measured as time to first such event. Secondary endpoints: Key Secondary Endpoints : 1. Coronary Heart Disease (CHD) death or subsequent non-fatal MI; 2. Cardiovascular Disease (CVD) death or subsequent non-fatal MI; 3. Subsequent non-fatal MI; 4.Coronary Heart Disease death; 5. Cardiovascular death; 6. All-cause death. Other Endpoints; Coronary
Heart Disease (CHD) death or subsequent non-fatal MI (type 1 or 4b);Subsequent Non-fatal MI (type 1 or 4b); Non-cardiovascular death; Invasive coronary angiography; Coronary revascularisation; Percutaneous coronary intervention; Coronary artery bypass graft; Proportion of patients prescribed ACS therapies during index hospitalisation; Proportion of patients discharged on preventative treatment or have alteration in dosage of preventative treatment during index hospitalisation; Length of stay for index hospitalisation; Representation or rehospitalisation with suspected ACS/recurrent chest pain within 12 months after index hospitalisation; Chest pain symptoms up to 12 months; Patient satisfaction at 1 month; Clinician certainty of presenting diagnosis after CTCA; Quality of Life (measured by EQ- 5D-5L up to12 months). Adverse Events and Serious Adverse Events; Proportion of patients with alternative cardiovascular diagnoses identified on CTCA; Proportion of patients with non-cardiovascular diagnosis identified on CTCA; Radiation exposure from CTCA as trial intervention. Cost effectiveness:
Estimated in terms of the lifetime incremental cost per quality-adjusted life year (QALY) gained.
SAMPLE SIZE: 1,749 patients.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
St Helier, Jersey
- Jersey General Hospital
-
-
-
-
-
Basildon, United Kingdom
- Basildon and Thurrock University Hospitals NHS Foundation Trust
-
Belfast, United Kingdom
- Ulster Hospital
-
Birmingham, United Kingdom
- Queen Elizabeth Hospital
-
Bournemouth, United Kingdom
- The Royal Bournemouth and Christchurch Hospital
-
Bradford, United Kingdom
- Bradford Royal Infirmary
-
Dudley, United Kingdom
- Russells Hall Hospital
-
Dundee, United Kingdom
- Ninewells Hospital
-
Edinburgh, United Kingdom, EH16 4SA
- Royal Infirmary Edinburgh
-
Glasgow, United Kingdom
- Glasgow Royal Infirmary
-
Glasgow, United Kingdom
- Queen Elizabeth University Hospital
-
Inverness, United Kingdom
- Raigmore Hospital
-
Kirkcaldy, United Kingdom
- Victoria Hospital
-
Leeds, United Kingdom
- Leeds General Infirmary
-
Lewisham, United Kingdom
- University Hospital Lewisham
-
London, United Kingdom
- Royal London Hospital
-
London, United Kingdom
- St. Thomas' Hospital
-
London, United Kingdom
- University Hospital North Tees
-
London, United Kingdom
- Whipps Cross Hospital
-
Luton, United Kingdom
- Luton & Dunstable Hospital
-
Melrose, United Kingdom
- Borders General Hospital
-
Milton Keynes, United Kingdom
- Milton Keynes University Hospital NHS Foundation Trust
-
Newcastle, United Kingdom
- Royal Victoria Infirmary
-
Plymouth, United Kingdom
- Derriford Hospital
-
Portsmouth, United Kingdom
- Queen Alexandra Hospital
-
Reading, United Kingdom
- Royal Berkshire NHS foundation trust
-
Redhill, United Kingdom
- East Surrey Hospital
-
Rotherham, United Kingdom
- Rotherham Hospital
-
Sandwell, United Kingdom
- Sandwell General Hospital
-
Sheffield, United Kingdom
- Northern General Hospital
-
Southampton, United Kingdom
- University Hospital Southampton Nhs Foundation Trust
-
Stoke, United Kingdom
- University Hospitals of the Midlands
-
Torquay, United Kingdom
- Torbay Hospital
-
Wolverhampton, United Kingdom
- New Cross Hospital
-
Worcester, United Kingdom
- Worcestershire Royal Hospital
-
Wrexham, United Kingdom
- Wrexham Maelor Hospital
-
Wythenshawe, United Kingdom
- University Hospital South Manchester
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
INCLUSION CRITERIA
Patient ≥18 years with symptoms mandating investigation for suspected or confirmed ACS with at least one of:
- ECG abnormalities e.g. ST segment depression >0.5 mm;
- History of ischaemic heart disease (where the clinician assessing patient confirms history based on patient history or available records);
- Troponin elevation above the 99th centile of the normal reference range or increase in high sensitivity troponin meeting European Society of Cardiology criteria for 'rule-in' or myocardial infarction (NB troponin assays will vary from site to site; local laboratory reference standards will be used).
EXCLUSION CRITERIA
Signs, symptoms, or investigations supporting high-risk ACS:
- ST elevation MI;
- ACS with signs or symptoms of acute heart failure or circulatory shock;
- Crescendo episodes of typical anginal pain;
- Marked or dynamic ECG changes e.g. ST depression of >3 mm
- Clinical team have scheduled early invasive coronary angiography on day of trial eligibility assessment.
Patient inability to undergo CT:
- Severe renal failure (serum creatinine >250 µmol/L or estimated glomerular filtration rate <30 mL/min);
- Contrast allergy;
- Beta blocker intolerance (if no alternative heart rate limiting agent available/suitable) or allergy ;
- Inability to breath hold;
- Atrial fibrillation (where mean heart rate is anticipated to be greater than 75 beats per minute after beta blockade).
- Patient has had invasive coronary angiography or CTCA within last 2 years and the previous investigation revealed obstructive coronary artery disease, or patient had either investigation within the last 5 years and the result was normal.
- Previous recruitment to the trial;
- Known pregnancy or currently breast feeding;
- Inability to consent;
- Further investigation for ACS would not in the patient's interest, due to limited life expectancy, quality of life or functional status;
- Prisoners
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: CT Coronary Angiogram
CT Coronary Angiogram plus standard care
|
Completion of a CT Coronary Angiogram
|
No Intervention: Standard Care
Standard care only
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The primary end-point will be all-cause death or subsequent non-fatal type 1 or type 4b MI at one year, measured as time to first such event.
Time Frame: 1 year
|
Myocardial infarction will be defined according to the most recent Universal Definition [Thygesen K, 2012] and will be adjudicated by two independent cardiologists blinded to the intervention.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Coronary Heart Disease (CHD) death or subsequent non-fatal MI
Time Frame: 1 year
|
Death or MI
|
1 year
|
Cardiovascular Disease (CVD) death or subsequent non-fatal MI
Time Frame: 1 year
|
CVD Death
|
1 year
|
Subsequent Non-fatal MI
Time Frame: 1 year
|
MI
|
1 year
|
Coronary Heart Disease death
Time Frame: 1 year
|
CHD Death
|
1 year
|
Cardiovascular death
Time Frame: 1 year
|
CVS Death
|
1 year
|
All-cause death
Time Frame: 1 year
|
Death
|
1 year
|
Coronary Heart Disease (CHD) death or subsequent non-fatal MI (type 1 or 4b)
Time Frame: 1 year
|
CHD and MI
|
1 year
|
Subsequent Non-fatal MI (type 1 or 4b)
Time Frame: 1 year
|
Non Fatal MI
|
1 year
|
Non-cardiovascular death
Time Frame: 1 year
|
Non CVS Death
|
1 year
|
Invasive coronary angiography
Time Frame: 1 year
|
Angiography procedures
|
1 year
|
Coronary revascularisation
Time Frame: 1 year
|
Revascularisation procedures
|
1 year
|
Percutaneous coronary intervention
Time Frame: 1 year
|
PCI interventions
|
1 year
|
Coronary artery bypass graft
Time Frame: 1 year
|
CABG procedures
|
1 year
|
Proportion of patients prescribed ACS therapies during index hospitalisation
Time Frame: 1 year
|
ACS therapies
|
1 year
|
Proportion of patients discharged on preventative treatment or have alteration in dosage of preventative treatment during index hospitalisation
Time Frame: 1 year
|
Preventative treatments
|
1 year
|
Length of Stay for Index Hospitalisation
Time Frame: 1 year
|
Length of Stay
|
1 year
|
Representation or rehospitalisation with suspected ACS/recurrent chest pain within 12 months after index hospitalisation
Time Frame: 1 year
|
Hospital attendances for ACS
|
1 year
|
Chest pain symptoms up to 12 months
Time Frame: 1 year
|
Patient symptoms measured by ROSE questionnaire
|
1 year
|
Quality of Life (measured by EQ-5D-5L up to 12 months)
Time Frame: 1 year
|
Quality of life measured by EQ-5D-5L questionnaire
|
1 year
|
Patient satisfaction at 1 month
Time Frame: 1 year
|
Participant questionnaire (11 questions) asking their viewpoint on the care they received during their baseline admission.
|
1 year
|
Clinician certainty of presenting diagnosis after CTCA
Time Frame: 1 year
|
Clinician certainty
|
1 year
|
Proportion of patients with alternative cardiovascular diagnoses identified on CTCA
Time Frame: 1 year
|
Safety assessment AE and SAEs
|
1 year
|
Proportion of patients with non-cardiovascular diagnosis identified on CTCA
Time Frame: 1 year
|
Safety Assessment AEs and SAEs
|
1 year
|
Radiation exposure from CTCA as trial intervention
Time Frame: 1 year
|
Safety Assessment AEs and SAEs
|
1 year
|
Cost effectiveness
Time Frame: 1 year
|
Estimated in terms of the lifetime incremental cost per quality-adjusted life year (QALY) gained.
|
1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Meah MN, Tzolos E, Wang KL, Bularga A, Dweck MR, Curzen N, Kardos A, Keating L, Storey RF, Mills NL, Slomka PJ, Dey D, Newby DE, Gray A, Williams MC, Roobottom C. Plaque Burden and 1-Year Outcomes in Acute Chest Pain: Results From the Multicenter RAPID-CTCA Trial. JACC Cardiovasc Imaging. 2022 Nov;15(11):1916-1925. doi: 10.1016/j.jcmg.2022.04.024. Epub 2022 Jun 15.
- Meah MN, Bularga A, Tzolos E, Chapman AR, Daghem M, Hung JD, Chiong J, Taggart C, Wereski R, Gray A, Dweck MR, Roobottom C, Curzen N, Kardos A, Felmeden D, Mills NL, Slomka PJ, Newby DE, Dey D, Williams MC. Distinguishing Type 1 from Type 2 Myocardial Infarction by Using CT Coronary Angiography. Radiol Cardiothorac Imaging. 2022 Oct 27;4(5):e220081. doi: 10.1148/ryct.220081. eCollection 2022 Oct.
- Gray AJ, Roobottom C, Smith JE, Goodacre S, Oatey K, O'Brien R, Storey RF, Curzen N, Keating L, Kardos A, Felmeden D, Lee RJ, Thokala P, Lewis SC, Newby DE. Early computed tomography coronary angiography in adults presenting with suspected acute coronary syndrome: the RAPID-CTCA RCT. Health Technol Assess. 2022 Aug;26(37):1-114. doi: 10.3310/IRWI5180.
- Gray AJ, Roobottom C, Smith JE, Goodacre S, Oatey K, O'Brien R, Storey RF, Curzen N, Keating L, Kardos A, Felmeden D, Lee RJ, Thokala P, Lewis SC, Newby DE; RAPID-CTCA Investigators. Early computed tomography coronary angiography in patients with suspected acute coronary syndrome: randomised controlled trial. BMJ. 2021 Sep 29;374:n2106. doi: 10.1136/bmj.n2106. Erratum In: BMJ. 2022 Feb 21;376:o438.
- Gray AJ, Roobottom C, Smith JE, Goodacre S, Oatey K, O'Brien R, Storey RF, Na L, Lewis SC, Thokala P, Newby DE. The RAPID-CTCA trial (Rapid Assessment of Potential Ischaemic Heart Disease with CTCA) - a multicentre parallel-group randomised trial to compare early computerised tomography coronary angiography versus standard care in patients presenting with suspected or confirmed acute coronary syndrome: study protocol for a randomised controlled trial. Trials. 2016 Dec 7;17(1):579. doi: 10.1186/s13063-016-1717-2.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RAPID-CTCA-2014
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Coronary Syndrome
-
Yonsei UniversityRecruitingCoronary Artery Disease, Acute Coronary SyndromeKorea, Republic of
-
Meditrix CorpNational University of Ireland, Galway, Ireland; Boston Scientific Japan K.K.; Fujita Health UniversityRecruitingChronic Coronary Syndrome | Non ST Segment Elevation Acute Coronary SyndromeJapan, Ireland
-
OrbusNeichDuke Clinical Research Institute; OrbusNeich Medical K.K.CompletedCoronary Arteriosclerosis | Non ST Segment Elevation Acute Coronary SyndromeUnited States, Japan
-
Medical University of WarsawRecruitingAcute Coronary Syndrome | Chronic Coronary Syndrome | Non ST Segment Elevation Acute Coronary SyndromePoland
-
Niguarda HospitalCompletedAcute Coronary Syndrome With ST Elevation on Electrocardiogram | Acute Coronary Syndrome Without ST Elevation on Electrocardiogram | Noncritical Coronary Artery Disease Coronary Stenosis Less Than 50 Per Cent | Aortic AneurysmsItaly
-
Sohag UniversityRecruitingLeft Main Coronary Artery Disease With Acute Coronary SyndromeEgypt
-
Eli Lilly and CompanyDaiichi Sankyo, Inc.CompletedCoronary Arteriosclerosis | Acute Coronary SyndromesUnited States
-
University of PatrasCompletedCoronary Artery Disease (CAD) | Acute Coronary Syndrome (ACS)Greece
-
The First Affiliated Hospital with Nanjing Medical...Unknown
-
Yonsei UniversityCompletedAcute Coronary Syndrome (ACS)Korea, Republic of
Clinical Trials on CT Coronary Angiogram
-
University of Texas Southwestern Medical CenterCompletedAcute Chest PainUnited States
-
University of Texas Southwestern Medical CenterRecruiting
-
University of MichiganCompletedCoronary Artery Disease | PsoriasisUnited States
-
ECRI bvGE Healthcare; HeartFlow, Inc.CompletedHeart Diseases | Cardiovascular Diseases | Multivessel Coronary Artery Disease | Coronary Artery DiseasesBelgium, France, Germany, Italy, Switzerland
-
University College, LondonUnknown
-
University of EdinburghCompletedMyocardial Infarction | Fibrosis | Neovascularization, PathologicUnited Kingdom
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceCompletedOut-of-Hospital Cardiac ArrestFrance
-
Icahn School of Medicine at Mount SinaiEnrolling by invitationAngina | Non-obstructive Coronary Artery DiseaseUnited States
-
Canadian Institutes of Health Research (CIHR)Completed
-
University of EdinburghCompletedFibrosis | Aortic Stenosis | Neovascularization, PathologicUnited Kingdom